Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Non-alcoholic fatty liver disease (NAFLD) is an ominous condition encompassing a wide range of liver histologic abnormalities, varying from simple triglyceride accumulation in hepatocytes (liver steatosis), non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma [1]. NAFLD is a risk factor for type 2 diabetes (T2D) [2] and cardiovascular disease [3]. In addition, almost the totality of people with T2D has NAFLD [4,5], often in its most severe forms [6]. This epidemiological association reflects the fact that NAFLD and T2D share causative factors, pathophysiological mechanisms, and likely, possible therapeutic strategies [7].

Source: Diabetes Research and Clinical Practice - July 23, 2021 Category: Endocrinology Authors: Giuseppe Della Pepa, Marco Russo, Marilena Vitale, Fabrizia Carli, Claudia Vetrani, Maria Masulli, Gabriele Riccardi, Olga Vaccaro, Amalia Gastaldelli, Angela A. Rivellese, Lutgarda Bozzetto Source Type: research